VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

178

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

September 22, 2022

Study Completion Date

May 22, 2023

Conditions

SARS-CoV-2 Infection

Interventions

BIOLOGICAL

VLA2001

whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide

Trial Locations (4)

Optimal Clinical Trials, Auckland

Middlemore Clinical Trials, Auckland

General Practitioners Research Institute (GPRI), Groningen

European Clinical Research Alliance on Infectious Diseases (ECRAID), Utrecht

All Listed Sponsors

lead

Valneva Austria GmbH

INDUSTRY